[{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual thin film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Orally dissolving thin film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Orally dissolving thin film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Orally Dissolving Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Alpha-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by BioXcel Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : Strengthened cash position will support advancement of SERENITY trial, to evaluate BXCL501, an ODT of dexmedetomidine, for agitation associated with bipolar disorders or schizophrenia.

                          Product Name : Igalmi

                          Product Type : HPAPI

                          Upfront Cash : Undisclosed

                          March 11, 2025

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : $14.0 million

                          Deal Type : Financing

                          blank

                          02

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : An orally dissolving film formulation of BXCL501 (dexmedetomidine), in the at-home setting is being investigated for acute treatment of agitation associated with bipolar disorders or schizophrenia.

                          Product Name : Igalmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 07, 2025

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : The proceeds from the financing will be used to commercialize Igalmi (dexmedetomidine HCl). It is being indicated for the treatment of agitation associated with schizophrenia.

                          Product Name : Igalmi

                          Product Type : HPAPI

                          Upfront Cash : Undisclosed

                          March 04, 2025

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Rodman & Renshaw LLC

                          Deal Size : $14.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : BXCL501 (dexmedetomidine Hc;) is being evaluated in the late-stage clinical trials studies for the treatment of Agitation Associated with Bipolar Disorders and Schizophrenia.

                          Product Name : BXCL501

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 12, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : BXCL501 (dexmedetomidine HCl) is an adrenergic receptor alpha-2 agonist, which is currently being evaluated for the treatment of Bipolar Disorder and Schizophrenia.

                          Product Name : Igalmi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 19, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : Igalmi (dexmedetomidine) sublingual film is being evaluated in late-stage clinical trial studies for the treatment of agitation associated with schizophrenia or bipolar I or II disorder.

                          Product Name : Igalmi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : BXCL501 (dexmedetomidine HCl) is an adrenergic receptor alpha-2 agonist, small molecule drug candidate, which is currently being evaluated for agitation associated With alzheimer’s dementia.

                          Product Name : Igalmi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 10, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to fund planned clinical trials of BXCL501 (sublingual dexmedetomidine), being evaluated for the treatment of Opioid Use Disorder.

                          Product Name : BXCL501

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 25, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $25.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : The company plans to focus on commercializing Igalmi (dexmedetomidine), FDA-approved for acute agitation treatment in schizophrenia and bipolar I or II disorder.

                          Product Name : Igalmi

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 13, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : BofA Securities

                          Deal Size : $60.0 million

                          Deal Type : Termination

                          blank

                          10

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : BXCL701 (talabostat mesylate) is an oral small molecule DPP inhibitor under investigation for small cell neuroendocrine prostate cancer treatment.

                          Product Name : BXCL701

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 12, 2024

                          Lead Product(s) : Talabostat Mesylate,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank